Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders

[1]  M. Hallek,et al.  Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG) , 2009, British journal of haematology.

[2]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[3]  T. Robak,et al.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Steele,et al.  Alemtuzumab in the Treatment of Refractory Acute Rejection and Bronchiolitis Obliterans Syndrome After Human Lung Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  H. Döhner,et al.  Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG). , 2007 .

[6]  J. Byrd,et al.  Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101. , 2007 .

[7]  M. Hallek,et al.  Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG). , 2007 .

[8]  V. Petrizzi,et al.  Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL). , 2007 .

[9]  C. Flowers,et al.  Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL). , 2007 .

[10]  R. Greil,et al.  Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL. , 2007 .

[11]  S. Pileri,et al.  Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. , 2007, Blood.

[12]  L. Sehn,et al.  Alemtuzumab in clinical practice: A British Columbia experience , 2007, Leukemia & lymphoma.

[13]  S. Knechtle,et al.  Alemtuzumab Induction and Recurrence of Glomerular Disease After Kidney Transplantation , 2007, Transplantation.

[14]  M. Grever,et al.  Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Sander,et al.  Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation , 2006, Leukemia.

[16]  H. Kantarjian,et al.  The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL). , 2006 .

[17]  M. Andreeff,et al.  Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL. , 2006 .

[18]  Emanuela M. Ghia,et al.  Fludarabine, Ara-c, novantrone and dexamethasone plus Campath-1H for the treatment of patients with chronic lymphocytic leukemia (CLL) and adverse clinical and biologic prognostic features. , 2006 .

[19]  R. Greil,et al.  Planned First Safety and Efficacy Analysis of Oral Fludarabine Combined with Subcutaneous Alemtuzumab in 2 nd Line Therapy of B-Chronic Lymphocytic Leukaemia (B-CLL): The FLUSALEM Study. , 2006 .

[20]  M. Hallek,et al.  Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG). , 2006 .

[21]  R. Greil,et al.  Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia , 2006, Cancer.

[22]  R. Greil,et al.  Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. , 2006, Cancer treatment reviews.

[23]  A. Pettitt,et al.  Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects , 2006, Leukemia.

[24]  P. Morris,et al.  Alemtuzumab (Campath-1H): A Systematic Review in Organ Transplantation , 2006, Transplantation.

[25]  F. Ricci,et al.  Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Delgado,et al.  Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. , 2006, Blood.

[27]  M. Hallek,et al.  T-PLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL. , 2005 .

[28]  Hazem A. Sayala,et al.  Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). , 2005 .

[29]  M. Hallek,et al.  Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Fegan,et al.  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Kimby,et al.  Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. , 2004, Blood.

[32]  H. Döhner,et al.  Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) , 2004, Leukemia.

[33]  Lisa L. Smith,et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.

[34]  M. Erlanson,et al.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.

[35]  E. Thiel,et al.  Efficacy and Tolerability of Alemtuzumab (CAMPATH-1H) in the Salvage Treatment of B-Cell Chronic Lymphocytic Leukemia—Change of Regimen Needed? , 2004, Leukemia & lymphoma.

[36]  T. Robak.  Monoclonal antibodies in the treatment of autoimmune cytopenias , 2004, European journal of haematology.

[37]  R. Kurzrock,et al.  Phase II study of alemtuzumab in chronic lymphoproliferative disorders , 2003, Cancer.

[38]  M. Andreeff,et al.  Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. , 2003, Blood.

[39]  R. Mercier,et al.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  E. Kimby,et al.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). , 2002, Blood.

[41]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[42]  A. Rawstron,et al.  Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. , 2002, Blood.

[43]  D. Catovsky,et al.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. , 2001, Blood.

[44]  G. Hale,et al.  The CD52 antigen and development of the CAMPATH antibodies. , 2001, Cytotherapy.

[45]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[46]  M. Dyer,et al.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  E. Montserrat,et al.  5th International Workshop on Chronic Lymphocytic Leukemia. , 1992, Leukemia research.

[48]  E. Montserrat.  New prognostic markers in CLL. , 2006, Hematology. American Society of Hematology. Education Program.

[49]  D. Catovsky,et al.  The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. , 2005, Haematologica.

[50]  M. Colombi,et al.  A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. , 2005, Haematologica.

[51]  B. Leber,et al.  Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.